---
title: "Tvardi Therapeutics (TVRD) Gets a Sell from Barclays"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295203580.md"
description: "Barclays analyst Etzer Darout maintained a Sell rating on Tvardi Therapeutics (TVRD) with a $3.00 price target, citing his focus on the Healthcare sector. While Darout has a strong historical performance record, the broader analyst consensus for TVRD remains a Moderate Buy with a higher average price target of $10.29."
datetime: "2026-08-07T08:38:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295203580.md)
  - [en](https://longbridge.com/en/news/295203580.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295203580.md)
generator: "portal-rs"
---

# Tvardi Therapeutics (TVRD) Gets a Sell from Barclays

In a report released today, Etzer Darout from Barclays maintained a Sell rating on Tvardi Therapeutics, with a price target of $3.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Darout covers the Healthcare sector, focusing on stocks such as Incyte, Abivax SA Sponsored ADR, and Tvardi Therapeutics. According to TipRanks, Darout has an average return of 29.4% and a 60.00% success rate on recommended stocks. 

Tvardi Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $10.29.

### Related Stocks

- [TVRD.US](https://longbridge.com/en/quote/TVRD.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [INCY.US](https://longbridge.com/en/quote/INCY.US.md)
- [ABVX.US](https://longbridge.com/en/quote/ABVX.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)

## Related News & Research

- [Tvardi Therapeutics: TTI-109 advanced for UC after positive topline results; Q2 net loss was $6.5 million](https://longbridge.com/en/news/295925308.md)
- [Tvardi Therapeutics to host KOL webinar on TTI-109 potential in ulcerative colitis](https://longbridge.com/en/news/295662355.md)
- [LifeSci Capital Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)](https://longbridge.com/en/news/296003421.md)
- [Piper Sandler Reaffirms Their Buy Rating on Akebia Therapeutics (AKBA)](https://longbridge.com/en/news/296105482.md)
- [US families, healthcare providers under strain after Trump crackdown on Haitian immigrants](https://longbridge.com/en/news/296335867.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**